Literature DB >> 21829417

Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid?

Marie-Olivia Chandesris1, David Ghez, Caroline Besson, Felipe Suarez, Richard Delarue, Marie-Thérèse Rubio, Ali Bazarbachi, Bruno Varet, Olivier Hermine.   

Abstract

Despite improvements in therapeutic options, human T cell lymphotropic virus type 1 (HTLV-1)-related adult T cell leukaemia/lymphoma (ATLL) has a dismal prognosis. The present report concerns the case of a multirelapsing ATLL that reached a complete remission following the treatment of a secondary acute promyelocytic leukaemia with cytarabine, anthracyclin, all-transretinoic acid and arsenic trioxide. This unexpected result with a multitreated/chemorefractory disease led us to reconsider the potential therapeutic benefits of arsenic trioxide, which has demonstrated efficacy against ATLL cells.

Entities:  

Year:  2009        PMID： 21829417      PMCID： PMC3030139          DOI： 10.1136/bcr.01.2009.1449

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  15 in total

1.  Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation.

Authors:  M E El-Sabban; R Nasr; G Dbaibo; O Hermine; N Abboushi; F Quignon; J C Ameisen; F Bex; H de Thé; A Bazarbachi
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

Review 2.  Proapoptotic regimes for HTLV-I-transformed cells: targeting Tax and the NF-kappaB pathway.

Authors:  Y Kfoury; R Nasr; O Hermine; H de Thé; A Bazarbachi
Journal:  Cell Death Differ       Date:  2005-08       Impact factor: 15.828

Review 3.  Global epidemiology of HTLV-I infection and associated diseases.

Authors:  Fernando A Proietti; Anna Bárbara F Carneiro-Proietti; Bernadette C Catalan-Soares; Edward L Murphy
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

4.  Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma.

Authors:  Kenji Ishitsuka; Junji Suzumiya; Mikiko Aoki; Kentaro Ogata; Shuuji Hara; Kazuo Tamura
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

5.  Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.

Authors:  Shawn A Hill; Patricia A Lloyd; Shannon McDonald; Jennifer Wykoff; David Derse
Journal:  J Infect Dis       Date:  2003-07-10       Impact factor: 5.226

6.  The efficacy of combined therapy of arsenic trioxide and alpha interferon in human T-cell leukemia virus type-1-infected squirrel monkeys (Saimiri sciureus).

Authors:  Jean Michel Heraud; Frank Mortreux; Fabrice Merien; Hugues Contamin; Renaud Mahieux; Jean Francois Pouliquen; Eric Wattel; Antoine Gessain; Hugues de Thé; Ali Bazarbachi; Olivier Hermine; Mirdad Kazanji
Journal:  Antiviral Res       Date:  2006-02-28       Impact factor: 5.970

7.  Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.

Authors:  Ghassan S Dbaibo; Youmna Kfoury; Nadine Darwiche; Shoghag Panjarian; Lina Kozhaya; Rihab Nasr; Mazen Abdallah; Olivier Hermine; Marwan El-Sabban; Hugues de Thé; Ali Bazarbachi
Journal:  Haematologica       Date:  2007-06       Impact factor: 9.941

8.  Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells.

Authors:  Rihab Nasr; Andreas Rosenwald; Marwan E El-Sabban; Bertrand Arnulf; Pierre Zalloua; Yves Lepelletier; Françoise Bex; Olivier Hermine; Louis Staudt; Hugues de Thé; Ali Bazarbachi
Journal:  Blood       Date:  2003-01-30       Impact factor: 22.113

9.  A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma.

Authors:  Olivier Hermine; Isabelle Allard; Vincent Lévy; Bertrand Arnulf; Antoine Gessain; Ali Bazarbachi
Journal:  Hematol J       Date:  2002

10.  Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.

Authors:  Emmanuel Raffoux; Philippe Rousselot; Jöel Poupon; Marie-Thérèse Daniel; Bruno Cassinat; Richard Delarue; Anne-Laure Taksin; Delphine Réa; Agnès Buzyn; Annick Tibi; Geneviève Lebbé; Patricia Cimerman; Christine Chomienne; Jean-Paul Fermand; Hugues de Thé; Laurent Degos; Olivier Hermine; Hervé Dombret
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.